Recommendation 17

NHST&T does not yet know how it will secure the promised benefits from the laboratory infrastructure it has established. NHST&T’s November 2020 business case for a £10 billion expansion of its testing capability stated that a £150 million investment 30 C&AG’s report, Figure 6 31 Committee of Public Accounts, COVID-19: Test, track and trace (part 1), Forty-Seventh report of Session 2019–21, HC 932, 10 March 2021, para 2 32 Qq 64, 87; C&AG’s Report, paras 7, 12, 14, 2.15, 2.17 and Figure 12 33 Qq 87, 97–100 34 C&AG’s Report, para 2.11 35 Qq 97–100 Test and Trace update 15 in laboratory infrastructure would leave a lasting ‘legacy’ for NHS England, in terms of preparedness for future disease emergencies and early diagnostic capabilities for cancer and cardiovascular and metabolic diseases. However, the NAO found that NHS England and NHS Improvement had not been informed of this commitment at the time it was made and only recently began having discussions with NHST&T about potential legacy opportunities. We asked our witnesses how this had happened. The previous Head of NHST&T told us that they were surprised by the statement in the NAO report as they had ongoing discussions with NHS England and NHS Improvement about the importance of ensuring that better diagnostic capability was in place rather than having to be built from scratch. We noted that both the Department and NHS England signed off the account in the C&AG’s report as factually accurate.36 The November business case also committed to drawing up a detailed benefits realisation strategy by December 2020 setting out how benefits would be achieved from the £10 billion funding that NHST&T was requesting. However, the Department accepted that this was not yet in place. Without this, it is not clear what benefits are expected from this funding, who is responsible for delivering them or whether there are risks that need to be managed.37